Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 5/20 | 0.35 |
| ▸ | RORC | P51449 | 5/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2926312 | 0.87 | REN (0.34) | RENRORCMEN1MAPTCRHBP | |
| SCHEMBL2922570 | 0.87 | REN (0.34) | RENRORCMEN1MAPTCRHBP | |
| SCHEMBL4960585 | 0.87 | REN (0.34) | RENRORCMEN1MAPTCRHBP | |
| SCHEMBL2922568 | 0.87 | REN (0.34) | RENRORCMEN1MAPTCRHBP | |
| SCHEMBL3465765 | 0.87 | REN (0.35) | RENRORCMEN1MAPTCRHBP | |
| SCHEMBL3465766 | 0.87 | REN (0.35) | RENRORCMEN1MAPTCRHBP | |
| SCHEMBL13435408 | 0.87 | REN (0.35) | RENRORCMEN1MAPTCRHBP | |
| SCHEMBL3466477 | 0.86 | REN (0.34) | RENRORCMAPTBACE1 | |
| SCHEMBL3466439 | 0.86 | REN (0.35) | RENRORCMEN1MAPTCRHBP | |
| SCHEMBL8258251 | 0.85 | REN (0.38) | RENRORCMEN1MAPTCRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | REN, AGT, AGTR1 | REN 1/4885RORC 4757/4885MEN1 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.